Tirzepatide

Tirzepatide is a synthetic dual agonist targeting both Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors — a novel mechanism that distinguishes it from single-receptor GLP-1 agonists. Developed by Eli Lilly and FDA-approved under the name Mounjaro, it has demonstrated some of the most significant weight reduction and glycemic control results seen in metabolic research to date.

Mechanism By simultaneously activating GIP and GLP-1 receptors, Tirzepatide drives synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation. The addition of GIP receptor agonism is believed to enhance the metabolic benefits beyond what GLP-1 agonism alone can achieve, particularly in adipose tissue metabolism and energy homeostasis.

Research Areas: Obesity & body weight reduction · Glycemic control & insulin sensitivity · Appetite suppression · Lipid metabolism & cardiovascular risk · NAFLD/NASH research · Body composition

For research use only. Not for human consumption.